Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?
作者信息
Corte Carminia Maria Della, Cimmino Flora, Morgillo Floriana
机构信息
Department of Precision Medicine, Oncology, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
CEINGE Biotecnologie Avanzate, 80145 Naples, Italy.
出版信息
Explor Target Antitumor Ther. 2021;2(2):204-207. doi: 10.37349/etat.2021.00041. Epub 2021 Apr 30.
Abstract
摘要
相似文献
1
Analysis of DNA from liquid biopsy: new genetic biomarkers for cancer immunotherapy?液体活检DNA分析：癌症免疫疗法的新基因生物标志物？
Explor Target Antitumor Ther. 2021;2(2):204-207. doi: 10.37349/etat.2021.00041. Epub 2021 Apr 30.
2
Diagnosis, Monitoring, and Prognosis of Liquid Biopsy in Cancer Immunotherapy.液体活检在癌症免疫治疗中的诊断、监测和预后。
Methods Mol Biol. 2023;2695:127-143. doi: 10.1007/978-1-0716-3346-5_9.
3
[Genomic Analysis and Immunotherapy by Liquid Biopsy].[液体活检的基因组分析与免疫治疗]
Gan To Kagaku Ryoho. 2019 Sep;46(9):1361-1366.
4
Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives.液体活检在非小细胞肺癌免疫治疗中的应用：现状、挑战与展望。
Cell Death Dis. 2023 Mar 31;14(3):230. doi: 10.1038/s41419-023-05757-5.
5
Immunotherapy in Breast Cancer and the Potential Role of Liquid Biopsy.乳腺癌中的免疫疗法及液体活检的潜在作用
Front Oncol. 2022 Mar 15;12:802579. doi: 10.3389/fonc.2022.802579. eCollection 2022.
6
Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.液体活检在黑色素瘤中的作用：在诊断、预测和治疗监测中的意义。
Int J Mol Sci. 2021 Sep 8;22(18):9714. doi: 10.3390/ijms22189714.
7
Liquid biopsy biomarkers to guide immunotherapy in breast cancer.液体活检生物标志物指导乳腺癌免疫治疗。
Front Immunol. 2023 Nov 23;14:1303491. doi: 10.3389/fimmu.2023.1303491. eCollection 2023.
8
The amount of DNA combined with TP53 mutations in liquid biopsy is associated with clinical outcome of renal cancer patients treated with immunotherapy and VEGFR-TKIs.液体活检中与 TP53 突变相结合的 DNA 数量与接受免疫治疗和 VEGFR-TKIs 治疗的肾癌患者的临床结局相关。
J Transl Med. 2022 Aug 16;20(1):371. doi: 10.1186/s12967-022-03557-7.
9
Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy.免疫疗法在非小细胞肺癌中的应用：液体活检的现状和未来前景。
Cancer Immunol Immunother. 2021 May;70(5):1177-1188. doi: 10.1007/s00262-020-02752-z. Epub 2020 Oct 28.
10
Liquid biomarkers in melanoma: detection and discovery.黑色素瘤的液体生物标志物：检测与发现。
Mol Cancer. 2018 Jan 17;17(1):8. doi: 10.1186/s12943-018-0757-5.
引用本文的文献
1
Novel applications of liquid Biopsy: Comprehensive methodology for circulating biomarker exploration in peripheral blood.液体活检的新应用：外周血中循环生物标志物探索的综合方法
J Liq Biopsy. 2025 Jun 26;9:100307. doi: 10.1016/j.jlb.2025.100307. eCollection 2025 Sep.
本文引用的文献
1
Circulating biomarkers in malignant pleural mesothelioma.恶性胸膜间皮瘤中的循环生物标志物
Explor Target Antitumor Ther. 2020;1(6):434-451. doi: 10.37349/etat.2020.00028. Epub 2020 Dec 28.
2
Role of liquid biopsy for thoracic cancers immunotherapy.液体活检在胸段癌症免疫治疗中的作用。
Explor Target Antitumor Ther. 2020;1(3):183-199. doi: 10.37349/etat.2020.00012. Epub 2020 Jun 29.
3
ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.循环肿瘤DNA浓度、MIKI67突变及超进展性疾病相关基因突变是卡瑞利珠单抗联合阿帕替尼多线治疗晚期非小细胞肺癌的预后标志物。
Front Oncol. 2020 Sep 4;10:1706. doi: 10.3389/fonc.2020.01706. eCollection 2020.
4
Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer.西妥昔单抗联合avelumab 诱导非小细胞肺癌自然杀伤抗体依赖性细胞细胞毒性和临床活性。
ESMO Open. 2020 Sep;5(5):e000753. doi: 10.1136/esmoopen-2020-000753.
5
Detection of PD-L1 Expression and Its Clinical Significance in Circulating Tumor Cells from Patients with Non-Small-Cell Lung Cancer.非小细胞肺癌患者循环肿瘤细胞中PD-L1表达的检测及其临床意义
Cancer Manag Res. 2020 Mar 19;12:2069-2078. doi: 10.2147/CMAR.S245425. eCollection 2020.
6
STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.STING 通路表达鉴定具有免疫应答表型的 NSCLC。
J Thorac Oncol. 2020 May;15(5):777-791. doi: 10.1016/j.jtho.2020.01.009. Epub 2020 Feb 15.
7
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.联合应用口服 CHK1 抑制剂 SRA737 和低剂量吉西他滨通过调节小细胞肺癌免疫微环境增强 PD-L1 阻断的疗效。
J Thorac Oncol. 2019 Dec;14(12):2152-2163. doi: 10.1016/j.jtho.2019.08.009. Epub 2019 Aug 27.
8
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.在非小细胞肺癌患者的三维球体培养物中，双重阻断 PD-L1 和 MEK 的抗肿瘤活性。
J Exp Clin Cancer Res. 2019 Jun 13;38(1):253. doi: 10.1186/s13046-019-1257-1.
9
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.利用下一代测序癌症基因 panel 评估血液肿瘤突变负担作为非小细胞肺癌患者免疫治疗的潜在生物标志物。
JAMA Oncol. 2019 May 1;5(5):696-702. doi: 10.1001/jamaoncol.2018.7098.
10
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.靶向 DNA 损伤反应通过 STING 介导的 T 细胞激活促进小细胞肺癌中的抗肿瘤免疫。
Cancer Discov. 2019 May;9(5):646-661. doi: 10.1158/2159-8290.CD-18-1020. Epub 2019 Feb 18.
Zotero 插件